Wide Ranks

ELDN

Eledon Pharmaceuticals, Inc.

4.26

Top Statistics
Market Cap 254 M Forward PE -4.58 Revenue Growth 0.00 %
Current Ratio 6.53 Trailing PE 5.84 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 78 M Total Cash Per Share 1.31 Total Debt 501000
Total Debt To Equity 0.6590 Current Ratio 6.53 Book Value Per Share 1.85
All Measures
Short Ratio 88.00 % Message Board Id finmb_62494905 Shares Short Prior Month 142854
Return On Equity -0.2536 City Irvine Uuid 2a495e4c-7ef2-3c4b-9213-71fbe48c07b6
Previous Close 4.25 First Trade Date Epoch Utc 1 B Book Value 1.85
Total Debt 501000 Volume 184453 Price To Book 2.31
Last Split Date 1 B Fifty Two Week Low 1.11 Total Cash Per Share 1.31
Shares Short Previous Month Date 1 B Target Median Price 10.00 Max Age 86400
Recommendation Mean 1.17 Sand P52 Week Change 0.3133 Target Mean Price 12.50
Net Income To Common -21223000 Short Percent Of Float 0.0137 Implied Shares Outstanding 59 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 250680
Average Volume10days 250680 Total Cash 78 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0004 Trailing PE 5.84 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 4.25 Target Low Price 7.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.50 Open 4.28
Free Cashflow -23197876 State CA Dividend Yield 0.00 %
Return On Assets -0.3336 Time Zone Short Name EST Trailing Eps 0.7300
Day Low 4.19 Address1 19900 MacArthur Boulevard Shares Outstanding 59 M
Price Hint 4 Target High Price 20.50 Website https://eledon.com
52 Week Change 2.70 Average Volume 373131 Forward Eps -1.20
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 626.10 %
Last Split Factor 1:18 Regular Market Day High 4.37 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 0.6590 Fifty Two Week High 5.54
Day High 4.37 Shares Short 731494 Regular Market Open 4.28
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0122 Operating Cashflow -37415000 Currency USD
Time Zone Full Name America/New_York Market Cap 254 M Is_nasdaq_100 False
Zip 92612 Quote Type EQUITY Industry Biotechnology
Long Name Eledon Pharmaceuticals, Inc. Regular Market Day Low 4.19 Held Percent Institutions 0.4288
Current Price 4.26 Address2 Suite 550 Financial Currency USD
Current Ratio 6.53 Industry Disp Biotechnology Number Of Analyst Opinions 5
Country United States Float Shares 46 M Two Hundred Day Average 2.66
Enterprise Value 176 M Forward PE -4.58 Regular Market Volume 184453
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.

The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.

It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation.

The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.

Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.